Compare Stocks: ARCT, OLMA, DSGN, and ABUS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$4.84 +2.8%	$4.58	$3.35 ▼ $5.38	$923.95M	0.64	1.29 million shs	1.45 million shs
ARCT Arcturus Therapeutics	$8.21 +0.9%	$6.81	$5.50 ▼ $24.17	$231.36M	2.39	541,611 shs	402,961 shs
DSGN Design Therapeutics	$15.27 +1.1%	$13.31	$4.68 ▼ $17.25	$928.09M	1.63	430,490 shs	917,955 shs
OLMA Olema Pharmaceuticals	$10.65 -1.1%	$11.26	$5.34 ▼ $36.26	$930.10M	2.03	960,416 shs	960,508 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	+2.76%	+3.64%	+6.14%	+10.76%	+43.20%
ARCT Arcturus Therapeutics	+0.86%	+9.18%	+35.70%	+20.38%	-54.16%
DSGN Design Therapeutics	+1.13%	+4.45%	+21.48%	+37.57%	+182.78%
OLMA Olema Pharmaceuticals	-1.11%	+2.11%	-7.15%	-23.71%	+84.90%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$4.84 +2.8%	$4.58	$3.35 ▼ $5.38	$923.95M	0.64	1.29 million shs	1.45 million shs
ARCT Arcturus Therapeutics	$8.21 +0.9%	$6.81	$5.50 ▼ $24.17	$231.36M	2.39	541,611 shs	402,961 shs
DSGN Design Therapeutics	$15.27 +1.1%	$13.31	$4.68 ▼ $17.25	$928.09M	1.63	430,490 shs	917,955 shs
OLMA Olema Pharmaceuticals	$10.65 -1.1%	$11.26	$5.34 ▼ $36.26	$930.10M	2.03	960,416 shs	960,508 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	+2.76%	+3.64%	+6.14%	+10.76%	+43.20%
ARCT Arcturus Therapeutics	+0.86%	+9.18%	+35.70%	+20.38%	-54.16%
DSGN Design Therapeutics	+1.13%	+4.45%	+21.48%	+37.57%	+182.78%
OLMA Olema Pharmaceuticals	-1.11%	+2.11%	-7.15%	-23.71%	+84.90%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABUS Arbutus Biopharma	2.50	Moderate Buy	$5.00	3.31% Upside
ARCT Arcturus Therapeutics	2.64	Moderate Buy	$24.25	195.37% Upside
DSGN Design Therapeutics	2.88	Moderate Buy	$16.50	8.06% Upside
OLMA Olema Pharmaceuticals	2.71	Moderate Buy	$42.40	298.12% Upside

Current Analyst Ratings Breakdown

Latest ARCT, OLMA, DSGN, and ABUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/17/2026	OLMA Olema Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	OLMA Olema Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$52.00 ➝ $46.00
8/12/2026	ABUS Arbutus Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C-)
8/11/2026	OLMA Olema Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$38.00 ➝ $36.00
8/11/2026	OLMA Olema Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$59.00
8/3/2026	OLMA Olema Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	ABUS Arbutus Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	ARCT Arcturus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	DSGN Design Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	OLMA Olema Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
5/22/2026	OLMA Olema Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 8/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABUS Arbutus Biopharma	$14.08M	68.01	N/A	N/A	$0.40 per share	12.10
ARCT Arcturus Therapeutics	$18.72M	12.46	N/A	N/A	$7.53 per share	1.09
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$3.73 per share	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	$5.88 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABUS Arbutus Biopharma	-$33.50M	$0.79	6.13	N/A	N/A	84.22%	90.98%	82.34%	N/A
ARCT Arcturus Therapeutics	-$65.78M	-$3.31	N/A	N/A	N/A	-317.62%	-46.54%	-36.46%	N/A
DSGN Design Therapeutics	-$69.79M	-$1.18	N/A	N/A	N/A	N/A	-34.03%	-32.05%	11/4/2026 (Estimated)
OLMA Olema Pharmaceuticals	-$162.45M	-$2.12	N/A	N/A	N/A	N/A	-48.26%	-43.04%	N/A

Latest ARCT, OLMA, DSGN, and ABUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ABUS Arbutus Biopharma	-$0.02	-$0.03	-$0.01	-$0.03	$0.70 million	$1.01 million
8/10/2026	Q2 2026	OLMA Olema Pharmaceuticals	-$0.5515	-$0.61	-$0.0585	-$0.61	N/A	N/A
8/6/2026	Q2 2026	ARCT Arcturus Therapeutics	-$0.9964	-$0.84	+$0.1564	-$0.84	$3.11 million	$2.96 million
8/3/2026	Q2 2026	DSGN Design Therapeutics	-$0.3443	-$0.32	+$0.0243	-$0.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
ARCT Arcturus Therapeutics	$0.71	8.71%	N/A	N/A	N/A
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABUS Arbutus Biopharma	N/A	81.42	81.42
ARCT Arcturus Therapeutics	N/A	5.88	5.88
DSGN Design Therapeutics	N/A	18.86	18.86
OLMA Olema Pharmaceuticals	0.01	8.86	8.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABUS Arbutus Biopharma	43.79%
ARCT Arcturus Therapeutics	94.54%
DSGN Design Therapeutics	56.64%
OLMA Olema Pharmaceuticals	91.78%

Insider Ownership

Company	Insider Ownership
ABUS Arbutus Biopharma	19.90%
ARCT Arcturus Therapeutics	17.80%
DSGN Design Therapeutics	17.10%
OLMA Olema Pharmaceuticals	12.56%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABUS Arbutus Biopharma	90	197.85 million	158.48 million	Optionable
ARCT Arcturus Therapeutics	180	28.42 million	23.36 million	Optionable
DSGN Design Therapeutics	40	62.58 million	51.88 million	Optionable
OLMA Olema Pharmaceuticals	70	87.50 million	76.51 million	Optionable

ARCT, OLMA, DSGN, and ABUS Headlines

Recent News About These Companies

Olema Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:OLMA)

August 18 at 7:59 PM | marketbeat.com

JPMorgan Chase & Co. Lowers Olema Pharmaceuticals (NASDAQ:OLMA) Price Target to $46.00

August 15, 2026 | americanbankingnews.com

HC Wainwright Has Negative Outlook for OLMA Q3 Earnings

August 15, 2026 | americanbankingnews.com

Piper Sandler Reaffirms Their Buy Rating on Olema Pharmaceuticals (OLMA)

August 13, 2026 | theglobeandmail.com

Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer

August 13, 2026 | markets.businessinsider.com

Olema Pharmaceuticals (OLMA) Receives a Buy from Goldman Sachs

August 13, 2026 | theglobeandmail.com

JPMorgan Chase & Co. Issues Pessimistic Forecast for Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price

August 13, 2026 | marketbeat.com

HC Wainwright Brokers Decrease Earnings Estimates for OLMA

August 13, 2026 | marketbeat.com

Citigroup Issues Pessimistic Forecast for Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price

August 13, 2026 | americanbankingnews.com

Olema Pharmaceuticals (NASDAQ:OLMA) Shares Gap Down Following Weak Earnings

August 13, 2026 | americanbankingnews.com

Olema Pharmaceuticals (NASDAQ:OLMA) Price Target Lowered to $59.00 at Citigroup

August 11, 2026 | marketbeat.com

Olema Pharmaceuticals (NASDAQ:OLMA) Shares Gap Down on Disappointing Earnings

August 11, 2026 | marketbeat.com

Olema Pharmaceuticals Q2 Loss Widens

August 11, 2026 | finance.yahoo.com

Olema Oncology Reports Second Quarter 2026 Financial and Operating Results

August 10, 2026 | finance.yahoo.com

Olema Pharmaceuticals (NASDAQ:OLMA) Releases Earnings Results, Misses Estimates By $0.08 EPS

August 10, 2026 | marketbeat.com

Olema Pharmaceuticals (OLMA) Expected to Post Earnings on Monday

August 9, 2026 | americanbankingnews.com

Dimensional Fund Advisors LP Acquires 123,790 Shares of Olema Pharmaceuticals, Inc. $OLMA

August 8, 2026 | marketbeat.com

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 4, 2026 | globenewswire.com

Olema Pharmaceuticals (OLMA) Expected to Release Quarterly Earnings on Monday

August 3, 2026 | marketbeat.com

Defilade Capital Management L.P. Acquires 269,902 Shares of Olema Pharmaceuticals, Inc. $OLMA

August 3, 2026 | marketbeat.com

Janus Henderson Group PLC Boosts Holdings in Olema Pharmaceuticals, Inc. $OLMA

August 1, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARCT, OLMA, DSGN, and ABUS Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

$4.84 +0.13 (+2.76%)

Closing price 08/18/2026 04:00 PM Eastern

Extended Trading

$4.55 -0.29 (-6.07%)

As of 04:34 AM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Arcturus Therapeutics NASDAQ:ARCT

$8.21 +0.07 (+0.86%)

Closing price 08/18/2026 04:00 PM Eastern

Extended Trading

$8.46 +0.25 (+3.11%)

As of 07:03 AM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Design Therapeutics NASDAQ:DSGN

$15.27 +0.17 (+1.13%)

Closing price 08/18/2026 04:00 PM Eastern

Extended Trading

$15.27 0.00 (0.00%)

As of 08/18/2026 07:30 PM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Olema Pharmaceuticals NASDAQ:OLMA

$10.65 -0.12 (-1.11%)

Closing price 08/18/2026 04:00 PM Eastern

Extended Trading

$10.73 +0.08 (+0.75%)

As of 04:01 AM Eastern

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARCT, OLMA, DSGN, and ABUS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARCT, OLMA, DSGN, and ABUS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARCT, OLMA, DSGN, and ABUS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARCT, OLMA, DSGN, and ABUS Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

Arcturus Therapeutics NASDAQ:ARCT

Design Therapeutics NASDAQ:DSGN

Olema Pharmaceuticals NASDAQ:OLMA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARCT, OLMA, DSGN, and ABUS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARCT, OLMA, DSGN, and ABUS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARCT, OLMA, DSGN, and ABUS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARCT, OLMA, DSGN, and ABUS Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

Arcturus Therapeutics NASDAQ:ARCT

Design Therapeutics NASDAQ:DSGN

Olema Pharmaceuticals NASDAQ:OLMA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools